Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Change In Receivables : $0.16 Mil (TTM As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Zynerba Pharmaceuticals Change In Receivables?

Zynerba Pharmaceuticals's change in receivables for the quarter that ended in Jun. 2023 was $-0.39 Mil. It means Zynerba Pharmaceuticals's Accounts Receivable increased by $0.39 Mil from Mar. 2023 to Jun. 2023 .

Zynerba Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2022 was $8.36 Mil. It means Zynerba Pharmaceuticals's Accounts Receivable declined by $8.36 Mil from Dec. 2021 to Dec. 2022 .

Zynerba Pharmaceuticals's Accounts Receivable for the quarter that ended in Jun. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Zynerba Pharmaceuticals's liquidation value for the three months ended in Jun. 2023 was $24.51 Mil.

Zynerba Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Zynerba Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynerba Pharmaceuticals Change In Receivables Chart

Zynerba Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

0.54

-11.17

5.57

-0.54

8.36

Zynerba Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Change In Receivables	Get a 7-Day Free Trial															-0.17	-0.10	0.91	-0.26	-0.39

Zynerba Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16 Mil.

Zynerba Pharmaceuticals (NAS:ZYNE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Zynerba Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Zynerba Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Zynerba Pharmaceuticals's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	35.968	-	11.456	+	0.75 * 0	+	0.5 * 0
=	24.51

Zynerba Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Zynerba Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zynerba Pharmaceuticals Inc (NAS:ZYNE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 West Lancaster Avenue, Suite 300, Devon, PA, USA, 19333

Website

http://www.zynerba.com

Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Executives

Kenneth T Jones	officer: See Remarks	C/O ZYNERBA PHARMACEUITCALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Brian Rosenberger	officer: VP, Commercial & Business Dev.	C/O ZYNERBA PHARMACEUTICALS, INC., 80 WEST LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Terri B Sebree	officer: President	ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
James E Fickenscher	officer: Chief Financial Officer	C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19087
Armando Anido	director, officer: Chairman & Chief Exec. Officer	80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Kenneth I Moch	director	68 WILLOW AVE, LARCHMONT NY 10538
Warren D Cooper	director	NUTRITION 21 INC, 4 MANHATTANVILLE ROAD, PURCHASE NY 10577
Pamela Stephenson	director	C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
John P. Butler	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Daniel L Kisner	director	2292 FARADAY AVENUE, CARLSBAD CA 92008
William J Federici	director	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Albert P Parker	officer: Chief Legal Officer	C/O ONCOCYTE CORPORATION, 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Suzanne M. Hanlon	officer: Sec, General Counsel & VP HR	80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Michael Rapp	10 percent owner	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Thomas L Harrison	director